Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

Biotalys Announces New Dates for the Publication of its 2025 Annual Report and for its Annual Shareholders Meeting

View original at globenewswire.com
Biotalys Announces New Dates for the Publication of its 2025 Annual Report and for its Annual Shareholders Meeting Ghent, BELGIUM, March 24, 2026 (GLOBE NEWSWIRE) -- Press release – regulated information Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solution…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company will require additional funds beyond May 2026 to meet its capital and expenditure needs and ensure its going concern even if the intended restructuring would be completed

    60% confidence

  • The company currently believes that the updated timeline will allow sufficient time to progress financing discussions, ensuring that the annual report and financial figures correctly reflect a more advanced status thereof

    60% confidence

  • Financing might eventually not be available or if available, might result in an important dilution of existing shareholders or not be available on commercially favourable terms

    60% confidence

  • No binding financing proposals are yet obtained

    60% confidence

  • The updated timeline will allow sufficient time to progress financing discussions, ensuring that the annual report and financial figures correctly reflect a more advanced status thereof

    60% confidence

  • No binding financing proposals are yet obtained

    60% confidence

  • No binding financing options or proposals are obtained by the company as of March 24, 2026

    60% confidence

  • Biotalys confirms it is in ongoing discussions with existing and new investors to obtain additional financing to support its operations in going concern

    60% confidence

  • The company has a cash runway until end of May 2026

    60% confidence

  • The company will require additional funds beyond May 2026 to meet its capital and expenditure needs and ensure its going concern even if the intended restructuring of the company would be completed

    60% confidence

  • Such financing might eventually not be available or if available, might result in an important dilution of existing shareholders or, in general, not be available on commercially favourable terms

    60% confidence

  • The company has a cash runway until end of May 2026

    60% confidence

  • Biotalys does not have sufficient working capital to cover the working capital needs for a period of at least 12 months

    60% confidence

  • The company is in ongoing discussions with existing and new investors to obtain additional financing to support its operations in going concern

    60% confidence

  • Biotalys does not have sufficient working capital to cover the working capital needs for a period of at least 12 months as of the date hereof and only has a cash runway until end of May 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com